Recent News

• 05.27.2025 - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
• 05.19.2025 - BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS
• 05.15.2025 - BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
• 05.15.2025 - BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
• 05.07.2025 - BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
• 05.06.2025 - BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
• 04.29.2025 - BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
• 04.10.2025 - BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS
• 03.31.2025 - BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Recent Filings

• 05.19.2025 - 8-K Current report
• 05.19.2025 - EX-99.1 EX-99.1
• 05.16.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.16.2025 - DEF 14A Other definitive proxy statements
• 05.16.2025 - ARS Annual Report to Security Holders
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - EX-99.1 EX-99.1
• 05.15.2025 - 8-K Current report
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2025 - PRE 14A Other preliminary proxy statements